Find A Research Study
Study Title: Liver Disease Registry and Tissue Repository
Category: Gastroenterology
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Kris Kowdley
Study Coordinator: Cheryl Saunders
Phone: 206 341 1786 Ext.11786
Email: gascjs@vmmc.org
What is the Liver Disease Registry and Tissue Repository study?
The purpose of the Liver Disease Registry and Repository is to learn more about the causes and effects of various liver diseases and to identify and maintain a list of patients who might be interested in participating in future clinical research studies related to his or her disease.
Who can participate?
Males and females of age 18 or greater who have been diagnosed with or are suspected to have the following liver diseases: Autoimmune Hepatitis (AIH), Hepatitis B (HBV), Hepatitis C (HCV), Nonalcoholic Fatty Liver Disease (NAFLD), Iron Overload, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), or Wilson’s Disease.
What do I have to do as a study participant?
The registry and repository is an observational study only and no treatment is involved. Participation involves the collection of health history and disease history as well as blood, urine, and/or liver tissue samples.
Study Summary:
The purpose of the Liver Disease Registry and Repository is to learn more about the causes and effects of various liver diseases and to identify and maintain a list of patients who might be interested in participating in future clinical research studies related to his or her disease.
Detailed Study Description:
(No information)
Study Design: Retrospective
Phase of Study: n/a
Study Type: Expanded Access
Condition or Study Focus: Cheryl Saunders
Intervention Type: Surveys/interview
Intervention Name: Surveys
Gender: Male and Female
Age group: Expanded Access
Sponsor: VMMC
Other studies in this category include:
Studies currently accepting study participants:
Studies currently not accepting study participants:
- 5-arm, parallel-group study of the effects on viral kinetics, safety and pharmacokinetics of different dosing regimens of Debio 025 in combination with peginterferon alpha-2a and ribavirin in chronic HCV genotype 1 patients who non-responders to standard
- A Phase 2b, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of GS-9450 in Adults with Chronic Hepatitis C Virus Infection
- A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001
- A study of INT-747 (6-ECDCA) in combination with ursodeoxycholic acid (URSO ®, UDCA) in patients with primary biliary cirrhosis
- Abatacept in Treatment of Patient with Active Crohns Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Abatacept in Treatment of Patient with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
- Boceprevir in Subjects with Previously Untreated Chronic HCV Genotype 1
- Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy
- RG1068 (Synthetic Human Secretin) – Enhanced MRCP in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis